Virtus ETF Advisers’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,490
| Closed | -$601K | – | 419 |
|
|
2021
Q3 | $601K | Sell |
3,490
-320
| -8% | -$41.9K | 0.26% | 117 |
|
|
2021
Q2 | $478K | Sell |
3,810
-1,000
| -21% | -$126K | 0.2% | 162 |
|
|
2021
Q1 | $652K | Buy |
4,810
+129
| +3% | +$16.7K | 0.28% | 115 |
|
|
2020
Q4 | $599K | Sell |
4,681
-1,448
| -24% | -$170K | 0.25% | 115 |
|
|
2020
Q3 | $690K | Buy |
6,129
+516
| +9% | +$51.4K | 0.36% | 108 |
|
|
2020
Q2 | $535K | Sell |
5,613
-6,051
| -52% | -$583K | 0.25% | 144 |
|
|
2020
Q1 | $1.05M | Sell |
11,664
-984
| -8% | -$76.5K | 0.43% | 102 |
|
|
2019
Q4 | $671K | Buy |
12,648
+5,927
| +88% | +$270K | 0.11% | 161 |
|
|
2019
Q3 | $266K | Sell |
6,721
-374
| -5% | -$16.2K | 0.05% | 207 |
|
|
2019
Q2 | $291K | Buy |
7,095
+1,285
| +22% | +$53.2K | 0.06% | 229 |
|
|
2019
Q1 | $271K | Sell |
5,810
-875
| -13% | -$38.4K | 0.58% | 68 |
|
|
2018
Q4 | $291K | Sell |
6,685
-6,419
| -49% | -$321K | 0.05% | 121 |
|
|
2018
Q3 | $750K | Sell |
13,104
-9,365
| -42% | -$460K | 0.08% | 70 |
|
|
2018
Q2 | $1.09M | Buy |
22,469
+1,648
| +8% | +$60K | 0.96% | 6 |
|
|
2018
Q1 | $814K | Buy |
20,821
+11,073
| +114% | +$471K | 0.71% | 69 |
|
|
2017
Q4 | $414K | Sell |
9,748
-1,229
| -11% | -$46.1K | 0.52% | 48 |
|
|
2017
Q3 | $410K | Buy |
10,977
+1,004
| +10% | +$34.9K | 0.06% | 106 |
|
|
2017
Q2 | $303K | Buy |
9,973
+272
| +3% | +$7.88K | 0.05% | 120 |
|
|
2017
Q1 | $257K | Buy |
9,701
+930
| +11% | +$24.5K | 0.05% | 159 |
|
|
2016
Q4 | $224K | Buy |
8,771
+1,861
| +27% | +$59K | 0.07% | 167 |
|
|
2016
Q3 | $250K | Hold |
6,910
| – | – | 0.12% | 124 |
|
|
2016
Q2 | $235K | Buy |
6,910
+1,154
| +20% | +$37.5K | 0.17% | 111 |
|
|
2016
Q1 | $152K | Buy |
+5,756
| New | +$167K | 0.21% | 119 |
|
Virtus ETF Advisers's XLRN Position: Q4 2021 in Review
Virtus ETF Advisers sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 3,490 shares — an estimated $601K sold.
Virtus ETF Advisers first reported a position in XLRN in Q1 2016 and held it in 23 quarters. The position peaked at $1.09M in Q2 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Virtus ETF Advisers reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Virtus ETF Advisers sold 3,490 Acceleron Pharma shares in Q4 2021, an estimated $601K.
- Virtus ETF Advisers first reported a position in Acceleron Pharma in Q1 2016 and held it in 23 quarters.
- Virtus ETF Advisers's Acceleron Pharma position peaked at $1.09M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.